PEPTIDE COMPARISON

Retatrutide vs Tirzepatide

An investigational triple agonist compared with an approved dual agonist.

QUICK ANSWER

Retatrutide vs Tirzepatide: the main difference.

Retatrutide’s published results are promising, but tirzepatide has the stronger decision-grade evidence today because it has completed larger programs and regulatory review. They are not interchangeable products.

Decision field	Retatrutide	Tirzepatide
Human research	Published Phase 2; Phase 3 development	Large Phase 3 and post-approval programs
Receptors	GIP + GLP-1 + glucagon	GIP + GLP-1
FDA status	Investigational; not approved	Approved products for defined indications
Availability	Clinical research only	Prescription medicine under labeled use
Evidence confidence	Promising but incomplete	High for labeled indications

SOURCES

Retatrutide vs Tirzepatide sources.

Human trial / 2023Triple-hormone-receptor agonist retatrutide for obesity — Phase 2New England Journal of Medicine / PubMed Registry / 2023Retatrutide Phase 2 obesity studyClinicalTrials.gov FDA / 2026FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. FDA FDA / 2026Zepbound prescribing informationU.S. FDA FDA / 2024FDA approves first medication for obstructive sleep apneaU.S. FDA

Retatrutide vs Tirzepatide: the main difference.

Retatrutide vs Tirzepatide sources.

Questions related to Retatrutide vs Tirzepatide.

Compare the next decision.